636 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study holds significant promise for improving long-term outcomes for adolescents undergoing bariatric surgery, a population often facing unique challenges in weight management. If semaglutide proves effective as …
This large-scale, real-world study is crucial for understanding the broader impact of semaglutide beyond controlled clinical trials, especially given its widespread use. The findings are expected to solidify the evide…
This Phase 4 clinical trial is crucial because it directly compares an established standard-of-care drug, metformin, with a newer, highly effective incretin therapy, semaglutide, in a real-world setting. The findings …
Developing new, potentially improved formulations of existing, effective drugs is crucial for enhancing patient convenience, adherence, and broader accessibility. If oral semaglutide D proves to be equally safe and ef…
The completion of this large Phase 3 trial is a significant milestone, as it represents a robust effort to explore a novel therapeutic avenue for Alzheimer's disease. If the results demonstrate a positive effect, it c…
Understanding the pharmacokinetic equivalence between daily and weekly dosing of semaglutide is crucial for optimizing drug development and patient care. If comparable steady-state exposure was achieved with daily adm…
Successfully demonstrating the acceptability and practicality of Tirzepatide in this population is crucial. If proven feasible, this intervention could offer a vital strategy to address obesity in breast cancer surviv…
If the EXER-MED trial demonstrates that combining exercise with tirzepatide leads to significantly better outcomes than medication alone, it could redefine the standard of care for obesity management. This research ha…
The successful completion of this Phase 1 study is a significant step forward in addressing pediatric obesity, a condition with limited pharmacological interventions. Tirzepatide, a dual GLP-1 and GIP receptor agonist…
The successful completion of this Phase 1/1b study is crucial for advancing TLC-6740 as a potential novel therapeutic agent for obesity and Type 2 Diabetes, conditions that continue to pose significant public health c…
The development of ALN-2232 represents a novel approach to treating obesity, potentially offering a new mechanism of action beyond existing therapies. If successful, this RNAi therapeutic could provide an important ne…
This study holds significant promise by exploring the potential for a novel, enhanced therapeutic approach for managing complex metabolic disorders like obesity and Type 2 Diabetes. By combining a specially formulated…
This study highlights a crucial, previously under-recognized aspect of GLP-1RA therapy: its potential impact on male sexual health. The finding that GLP-1RAs may increase the risk of erectile dysfunction suggests that…
Understanding drug-drug interactions is paramount for patient safety, especially with the increasing use of novel weight-loss medications like CagriSema. Many patients with obesity rely on medications such as atorvast…
This study is critically important because semaglutide (NN9535) is a widely used and highly effective treatment for Type 2 Diabetes. Understanding its pharmacokinetic profile in patients with renal impairment is vital…
This Phase 2 trial is highly significant as it explores a potential novel adjunctive therapy for Type 2 Diabetes patients who are not adequately controlled by current GLP-1-based treatments. If icovamenib proves effec…
Demonstrating the clinical comparability of drug products from different manufacturing processes is crucial for ensuring consistent drug quality, safety, and patient outcomes globally. This study's findings, once rele…
Preserving lean muscle mass during rapid weight loss is critical for maintaining metabolic rate, improving insulin sensitivity, and preventing weight regain, especially in individuals with Type 2 Diabetes Mellitus. Th…
The findings from this study are crucial because they will inform the safe and effective use of AD109 in a growing population of OSA patients who are also managing their weight or diabetes with GLP-1 medications. If A…
Obesity is a major comorbidity in breast cancer patients, negatively impacting treatment efficacy and increasing recurrence risk. This study is significant because it directly addresses the potential of a powerful wei…
This pilot study is critically important because it addresses a significant clinical challenge: achieving healthy weight loss in older adults without compromising vital muscle and bone mass. If Tirzepatide can demonst…
This case report highlights the potential efficacy and safety of GLP-1 receptor agonists (GLP1RAs), specifically semaglutide, in managing the challenging glycemic control associated with mitochondrial diabetes in pedi…
This review highlights a paradigm shift in how dysglycemia might be managed in acute care settings. If GLP-1 RAs prove safe and effective in this population, they could offer a novel therapeutic strategy to improve ou…
This follow-up study is critical for understanding the sustained impact of semaglutide on cardiovascular health and weight management after treatment cessation. The insights gained could inform long-term treatment str…
This pilot study is crucial because it addresses a significant unmet need for effective smoking cessation strategies in Type 2 diabetes patients, a group at high risk for cardiovascular complications. If semaglutide p…
The successful completion of this Phase 3 trial suggests semaglutide 2.4 mg could represent a significant advancement in the management of obesity and prediabetes. If the full results confirm substantial weight loss a…
If BGM0504 demonstrates comparable or superior efficacy to semaglutide with a favorable safety profile, it could represent a significant new therapeutic option for managing Type 2 Diabetes. This could provide a valuab…
If the results demonstrate a positive safety and efficacy profile, this study could pave the way for a novel adjunctive treatment strategy for a particularly challenging patient population. Adults with Type 1 Diabetes…
Establishing bioequivalence is crucial for pharmaceutical products, especially when manufacturing processes are altered, as it confirms that the drug's performance remains consistent. This finding means that patients …
The investigation of eloralintide, particularly in combination with tirzepatide, represents a significant step in developing next-generation treatments for obesity. If eloralintide demonstrates a favorable safety and …
Understanding the drug effect of Tirzepatide on musculoskeletal abnormalities is critical for optimizing obesity treatment strategies. This research could provide evidence for the necessity of combining GLP-1 therapie…
This study is significant because it explores a novel therapeutic approach for two intertwined and devastating conditions: Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease. If successful, tirzepatid…
This feasibility study could provide crucial preliminary evidence for a novel and highly effective treatment strategy for obesity-related hypertension in a vulnerable young adult population. If successful, it could es…
The identification of genetic predictors for GLP-1 response holds significant implications for personalized medicine in managing prediabetes, type 2 diabetes, and obesity. This research could lead to tailored therapeu…
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
Understanding the nuanced differences in how GLP-1 receptor agonists and gastric bypass surgery affect body composition is crucial for optimizing treatment strategies for obesity. If GLP-1 RAs can achieve similar bene…
This research is highly significant as it targets a critical unmet need in Type 2 Diabetes management: patients who do not achieve adequate glycemic control even with potent GLP-1 or GLP-1/GIP receptor agonists. LY345…
This Phase 2a study is crucial because it targets a specific genetic subtype of MASLD that is often more aggressive and difficult to treat. ALN-PNP works by reducing the PNPLA3 protein, which is implicated in liver fa…